tiprankstipranks
Trending News
More News >
Eckert & Ziegler Strahlen- und Medizintechnik AG (DE:EUZ)
XETRA:EUZ
Advertisement

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) AI Stock Analysis

Compare
22 Followers

Top Page

DE:EUZ

Eckert & Ziegler Strahlen und Medizintechnik

(XETRA:EUZ)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 4o)
Rating:58Neutral
Price Target:
€18.50
▲(4.58% Upside)
The overall stock score is primarily influenced by strong financial performance, which is offset by bearish technical indicators and a high valuation. The company's robust revenue growth and profitability are significant strengths, but the technical analysis suggests caution due to oversold conditions and downward momentum. The high P/E ratio indicates potential overvaluation, though the dividend yield offers some compensation.

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) vs. iShares MSCI Germany ETF (EWG)

Eckert & Ziegler Strahlen und Medizintechnik Business Overview & Revenue Model

Company DescriptionEckert & Ziegler Strahlen und Medizintechnik (EUZ) is a leading global provider of isotope-based medical technology and services, specializing in the development, production, and distribution of medical devices and systems for radiation therapy and nuclear medicine. The company operates in several sectors, including radiation therapy, diagnostics, and the manufacturing of radioisotopes for medical applications. EUZ's core products include brachytherapy devices, radiopharmaceuticals, and quality assurance solutions for medical imaging and treatment.
How the Company Makes MoneyEckert & Ziegler generates revenue through multiple streams, primarily by selling its advanced medical devices and radiopharmaceuticals to hospitals, clinics, and healthcare providers. The company also earns income from long-term contracts with healthcare institutions for the provision of nuclear medicine services and the supply of isotopes. Significant partnerships with healthcare organizations and research institutions enhance its market reach and product development capabilities. Additionally, EUZ may benefit from government contracts and grants related to healthcare innovation and technology advancements, which contribute to its overall earnings.

Eckert & Ziegler Strahlen und Medizintechnik Financial Statement Overview

Summary
Eckert & Ziegler Strahlen und Medizintechnik exhibits strong financial health with impressive revenue growth and solid profitability metrics. The balance sheet is stable, though rising debt levels warrant attention. Cash flow generation is robust, supporting the company's growth trajectory. Overall, the company is well-positioned in the medical devices industry, but careful management of cost pressures and debt is essential to sustain its financial performance.
Income Statement
85
Very Positive
Eckert & Ziegler Strahlen und Medizintechnik shows strong revenue growth with a TTM (Trailing-Twelve-Months) growth rate of 94.8%, indicating robust expansion. The company maintains healthy profitability with a gross profit margin of 48.05% and a net profit margin of 11.62%. EBIT and EBITDA margins are also solid at 21.58% and 27.70%, respectively, reflecting efficient operations. However, the slight decline in gross profit margin compared to previous periods suggests potential cost pressures.
Balance Sheet
78
Positive
The balance sheet is stable with a manageable debt-to-equity ratio of 0.25, indicating prudent leverage. Return on equity (ROE) is strong at 14.43%, showcasing effective use of equity capital. The equity ratio stands at 51.16%, reflecting a solid equity base. However, the increase in total debt over recent periods could pose a risk if not managed carefully.
Cash Flow
80
Positive
The company demonstrates strong cash flow generation with a free cash flow growth rate of 8.52% in the TTM period. The operating cash flow to net income ratio is high at 0.93, indicating efficient cash conversion. The free cash flow to net income ratio of 0.74 suggests good cash profitability. Despite these strengths, the volatility in free cash flow growth over the years highlights potential fluctuations in cash generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue299.26M295.85M246.09M222.26M180.44M176.14M
Gross Profit143.71M143.16M116.34M106.78M91.08M86.53M
EBITDA85.70M77.38M59.67M57.90M56.68M43.05M
Net Income36.64M33.28M26.30M29.28M34.53M21.29M
Balance Sheet
Total Assets438.88M442.40M439.36M416.84M347.73M292.00M
Cash, Cash Equivalents and Short-Term Investments112.37M118.36M68.00M82.70M95.02M88.61M
Total Debt48.57M55.34M56.30M49.59M26.97M20.40M
Total Liabilities212.82M217.18M215.27M203.21M155.20M143.08M
Stockholders Equity224.60M223.45M222.18M212.07M187.39M147.82M
Cash Flow
Free Cash Flow56.77M49.38M21.12M3.17M5.00M27.88M
Operating Cash Flow74.92M66.57M46.95M34.30M33.85M36.79M
Investing Cash Flow-28.46M-16.59M-42.74M-41.04M-23.59M-13.35M
Financing Cash Flow-20.79M-9.99M-9.28M-5.71M-6.06M-12.96M

Eckert & Ziegler Strahlen und Medizintechnik Technical Analysis

Technical Analysis Sentiment
Negative
Last Price17.69
Price Trends
50DMA
18.46
Negative
100DMA
20.06
Negative
200DMA
18.99
Negative
Market Momentum
MACD
-0.11
Negative
RSI
47.82
Neutral
STOCH
37.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:EUZ, the sentiment is Negative. The current price of 17.69 is above the 20-day moving average (MA) of 17.50, below the 50-day MA of 18.46, and below the 200-day MA of 18.99, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 37.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:EUZ.

Eckert & Ziegler Strahlen und Medizintechnik Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
€1.29B68.595.34%0.21%1.16%-43.53%
58
Neutral
€1.11B30.2317.61%2.83%9.42%9.54%
55
Neutral
€1.35B-61.384.97%0.10%-18.82%-113.85%
54
Neutral
€448.01M-2.64-27.21%-14.84%-338.52%
52
Neutral
€1.35B-45.554.97%0.13%-18.82%-113.85%
49
Neutral
€1.12B-7.55-18.39%-1.41%9.05%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
17.69
3.85
27.83%
DE:BIO
Biotest
38.00
-3.60
-8.65%
DE:BIO3
Biotest
28.20
0.54
1.95%
DE:COP
CompuGroup Medical
24.24
10.22
72.90%
DE:EVT
Evotec
6.74
0.60
9.84%
DE:FYB
Formycon AG
25.35
-28.15
-52.62%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025